April 29, 2010 (Orlando, Florida) — Taking a proton pump inhibitor (PPI) with a phosphate binder might improve phosphorus control in patients on hemodialysis, according to a retrospective study ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The type of ...

In a study, the risks for cardiovascular events and all-cause mortality were only a nonsignificant 4% lower for sevelamer vs calcium acetate recipients older than 65 years initiating hemodialysis. The ...

Cardiovascular mortality risks are no higher with these agents than with sevelamer, data show. Hyperphosphatemia is a common complication among patients with end-stage renal disease (ESRD) and is ...

A recent study has demonstrated that phosphate binders are safe and effective for controlling phosphorus levels in patients on peritoneal dialysis (PD). “Phosphate control strategies should be similar ...

Please provide your email address to receive an email when new articles are posted on . A new report from BioTrends Research group found that the use of phosphate binders in the United States has ...

Hemodialysis patients with mild to moderate hyperphosphatemia, hypercalcemia and hypercholesterolemia can benefit from the 'bonus effects' of sevelamer on lipids and inflammatory markers Abnormal ...

Wacker Chemie says it has earmarked $26 million to build a plant for making polymeric binders based on polyvinyl acetate and vinyl acetate copolymers at its site in Burghausen, Germany. The copolymers ...